AstraZeneca Investor Day Presentation Deck
Secondary endpoint: overall survival
28.6% maturity; trend towards improved OS with olaparib + abiraterone
Probability of OS
15
1.0
0.9-
0.8-
0.7-
0.6
0.5
0.4
0.3
0.2
0.1
0.0
No. at risk
Olaparib + abiraterone
Placebo + abiraterone
Events: 228.
10 12 14 16 18 20 22 24 26 28 30
Time from randomization (months)
4
399 398 398 394 391 387 385 379 374 369 364 359 349 343 333 322 316 313 290 263 231 193 159 135 116 92 73 51 37 24 11
397 394 392 386 385 383 381 377 374 371 368 363 353 345 335 322 314 308 286 258 223 186 151 121 104 88 63 44 22 13 6 0
0
2
4
6
8
32
1
0
COO
0
0
Events, n (%)
Median OS
(months)
HR (95% CI)
Olaparib +
abiraterone
(n=399)
107 (26.8)
NR
Placebo +
abiraterone
(n=397)
121 (30.5)
NR
0.86 (0.66-1.12)
P=0.29
Pre-specified 2-sided alpha: 0.001
3View entire presentation